Edwards Lifesciences Corp 4

Daniel J. Lippis, CVP, TAVR of Edwards Lifesciences Corp (EW), exercised 619 options and sold 619 shares of common stock on August 11, 2026 under a Rule 10b5-1 plan, modestly reducing his direct holdings.

On August 11, 2026, Daniel J. Lippis, CVP, TAVR of Edwards Lifesciences Corp, exercised 619 stock options at an exercise price of $72.68 per share, acquiring 619 shares of common stock, and on the same day sold 619 shares of common stock at $92.03 per share in a transaction effected under a Rule 10b5-1 trading plan, resulting in a net decrease of his directly held common stock from 40,652.9103 shares to 40,033.9103 shares. The option exercise generated shares that were fully offset by the sale, effectively a cashless exercise, with an estimated sale value of about $56,954 and option exercise cost of about $45,029, implying a modest net gain and leaving him with direct holdings valued at roughly $3.75 million based on the current share price. The filing notes that it reflects only the reported changes and may not include all securities beneficially owned by the reporting person.

Filing Facts

CIK

1099800

Ticker

EW

Form

4

Source Type

sec

Accession

0001225208-26-007065

Alert Tier

5